CDK7-IN-26

CDK7-IN-26 (compound 36) is an orally active CDK7 inhibitor (IC50: 7.4 nM) . CDK7-IN-26 potently inhibits the growth of triple-negative breast cancer (TNBC) cell line-derived xenograft (CDX) tumors in vivo and inhibits MDA-MB-453 cells in vitro with an IC50 of 0.15 μM[1].

Product Specifications

CAS Number

[3024545-79-4]

UNSPSC

12352005

Target

CDK

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/cdk7-in-26.html

Solubility

10 mM in DMSO

Smiles

O=P(C)(C1=C(C=CC2=C1NC=C2C3=NC(N[C@H]4C[C@H](F)CNC4)=NC5=C3SC=C5)C#N)C

Molecular Formula

C22H22FN6OPS

Molecular Weight

468.49

References & Citations

[1]Zhang H et al. Discovery and optimization of thieno [3, 2-d] pyrimidine derivatives as highly selective inhibitors of cyclin-dependent kinase 7[J]. European Journal of Medicinal Chemistry, 2023: 115955.